优立新治疗急性细菌性感染的临床观察

A clinical study of Unasyn in the treatment of acute bacterial infections

优立新与头孢噻肟随机对照治疗呼吸道和泌尿道感染４０例，临床有效率各为１００％和９５％（Ｐ＞０．０５），细菌阴转率各为９４，１％和１００％（Ｐ＞０．０５）。无显著性差异。优立新共治疗３０例，临床有效率和细菌阴转率分别为１００％和９６％。两药副反应均轻微。无因副反应而停药。在优立新治疗病例中，有２例出现皮疹。另２例为肝功能ＡＬＴ和ＡＳＴ暂时性轻度增高。

50 hospitalized patients were treated for acute respiratory tract, urinary tract, or other infections. In the randomized trial, there were 20 cases in either Unasyn (sulbactam/ampicillin)or Cefotaxime treatment group. The clinical efficacy rates were 100% for Unasyn and 95% for Cefotaxime(P>0.05),and the eradication rates of pathogens were 94.1% and 100% , respectively (P>0.05). Unasyn was administered to a total of 30 patients. Tbe clinical efficacy was 100% and the eradication rate of pathogens was 96% .No serious side effects of both drugs Were observed.